acyclovir
acyclovir is listed in the FDA National Drug Code directory with 62 NDC codes, marketed under brand names including ACYCLOVIR, Acyclovir, acyclovir. Available dosage forms: capsule, cream, tablet, ointment, injection, solution.
Drug details
- Generic Name
- acyclovir
- Brand Names
- ACYCLOVIR, Acyclovir, acyclovir, Zovirax
- Application Number
- ANDA074889
- Sponsor
- Cardinal Health 107, LLC
- NDC Codes
- 62
- Dosage Forms
- CAPSULE, CREAM, TABLET, OINTMENT, INJECTION, SOLUTION, SUSPENSION
- Routes
- ORAL, TOPICAL, INTRAVENOUS
- Active Ingredients
- ACYCLOVIR, ACYCLOVIR SODIUM
Indications and Usage
INDICATIONS AND USAGE Herpes Zoster Infections: Acyclovir tablets are indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir tablets are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir tablets are indicated for the treatment of chickenpox (varicella).
Warnings
WARNINGS Acyclovir tablets are intended for oral ingestion only. Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see ADVERSE REACTIONS : Observed During Clinical Practice and OVERDOSAGE ). Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy. Severe cutaneous adverse reactions (SCARs), including acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens- Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme (EM) have been reported with acyclovir (see CONTRAINDICATIONS and ADVERSE REACTIONS ). Discontinue acyclovir immediately if a painful rash with mucosal involvement or a progressive severe rash develops. Closely monitor clinical status and initiate appropriate therapy. Acyclovir is contraindicated in patients who have developed SCARs with the use of acyclovir or valacyclovir, or any component of the formulation (see CONTRAINDICATIONS and ADVERSE REACTIONS ).